ArticleFrontiers in pharmacology2022

First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China.

Jian Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.